Intercept nails $165M diabetes pact with Servier

Intercept Pharmaceuticals has struck a $165 million deal with Les Laboratoires Servier to collaborate on new TGR5 agonists for diabetes and other metabolic ailments. "We are very happy to enter into this collaboration with Intercept which will allow us to further expand our diabetes and metabolic disease franchise," stated Dr. Emmanuel Canet, head of Servier R&D. "TGR5 is a target of great interest with its effects on GLP-1 that complement those of other classes of marketed diabetes drugs." Release

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.